Details:

 

Description:

Flibanserin (flib an' ser in) is actually a serotonergic mixed agonist and antagonist that was initially developed as an antidepressant when it was located to possess feasible effects on sexual desire and drive. In vitro, flibanserin acts predominantly as a serotonin (5-HT) 1A receptor agonist, however it also has antagonist activity against other serotonin receptors, such as 5-HT 2C and 2B, also as significantly less defined activity at dopamine D4 receptors.

Flibanserin also has variable regional activities, growing or decreasing serotonin, dopamine and norepinephrine in unique brain places. Whilst its precise mechanism of action is unclear, flibanserin was located to improve subjective measures of sexual want and satisfaction in many large clinical trials accomplished largely in premenopausal girls who fulfilled the clinical criteria for hypoactive sexual want disorder. Flibanserin was authorized for use within the Usa in 2015 for use in remedy of hypoactive sexual desire disorder in premenopausal ladies. There is restricted clinical expertise with its use. Concurrent alcohol use is considered contraindicated when taking flibanserin, and caution is advisable against its use with antidepressants or sedatives and in patients wtih hepatic impairment. Flibanserin is readily available in tablets of one hundred mg under the commercial name Addyi. The encouraged dose is 100 mg when day-to-day at bedtime. Prevalent unwanted effects include dizziness, fatigue, somnolence, insomnia, nausea and drug mouth. Much less popular, but potentially severe side effects contain hypotension, syncope and next day somnolence or sedation. Due to the severity of these adverse events, flibanserin is offered only as a part of a rigorous Danger Evaluation and Mitigration Tactic (REMS) that needs registration, certification of the prescribers and pharmacies, and typical reporting.

 

COA:

 

 

 
Packing:
 

 
 

Flibanserin Sex Health Supplements Sexual Desire for Women CAS 167933-07-5